
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated a robust financial performance with shares experiencing a notable increase of approximately 7% in the after-market, attributed to strong Q4 results and optimistic revenue guidance. The company's operating margin expansion of at least 750 basis points suggests an operating margin exceeding 16%, indicating improved profitability. Additionally, potential growth drivers such as new product launches, faster adoption rates in heart and lung transplants, and international market expansion present significant opportunities for sustained financial performance and value creation in the years ahead.
Bears say
TransMedics Group Inc. is experiencing a decline in operating margins, projected to decrease by 250 basis points due to substantial investments in its clinical pipeline and international infrastructure. Additionally, despite achieving a year-over-year increase in product revenues of 33.1% and service revenues of 30.9%, the company's gross margins fell to 58.1%, which is 230 basis points below expectations. Further complicating the outlook are risks related to the potential for disappointing adoption rates of the Organ Care System (OCS), increasing competition leading to market share losses, and possible reimbursement changes that could negatively impact demand for the company's products and services.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares